Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | IMA402 |
Synonyms | |
Therapy Description |
IMA402 is a bispecific T-cell engaging receptor targeting an HLA-A*02-presented peptide derived from PRAME, which potentially leads to tumor cell killing and inhibition of tumor growth (Blood (2022) 140 (Supplement 1): 9089-9090). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMA402 | IMA-402|IMA 402 | IMA402 is a bispecific T-cell engaging receptor targeting an HLA-A*02-presented peptide derived from PRAME, which potentially leads to tumor cell killing and inhibition of tumor growth (Blood (2022) 140 (Supplement 1): 9089-9090). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05958121 | Phase Ib/II | IMA402 | IMA402 T Cell-Engaging Receptor Molecule (TCER) in Recurrent and/or Refractory Solid Tumors | Recruiting | DEU | 0 |